Celldex Therapeutics Company Profile (NASDAQ:CLDX)

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLDX
  • CUSIP: 15117B10
  • Web: www.celldextherapeutics.com
Capitalization:
  • Market Cap: $385.02 million
  • Outstanding Shares: 128,341,000
Average Prices:
  • 50 Day Moving Avg: $2.79
  • 200 Day Moving Avg: $2.76
  • 52 Week Range: $2.20 - $5.02
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.08
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $9.46 million
  • Price / Sales: 40.16
  • Book Value: $1.82 per share
  • Price / Book: 1.63
Profitability:
  • EBITDA: ($115,220,000.00)
  • Net Margins: -1,318.94%
  • Return on Equity: -51.87%
  • Return on Assets: -37.19%
Debt:
  • Current Ratio: 5.56%
  • Quick Ratio: 5.56%
Misc:
  • Average Volume: 1.44 million shs.
  • Beta: 2.72
  • Short Ratio: 13.59
 

Frequently Asked Questions for Celldex Therapeutics (NASDAQ:CLDX)

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.23) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.05. The company earned $3.83 million during the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business's quarterly revenue was up 175.5% on a year-over-year basis. During the same period last year, the business earned ($0.32) EPS. View Celldex Therapeutics' Earnings History.

When will Celldex Therapeutics make its next earnings announcement?

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Celldex Therapeutics.

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?

7 brokers have issued 1 year price objectives for Celldex Therapeutics' stock. Their predictions range from $3.00 to $10.00. On average, they expect Celldex Therapeutics' stock price to reach $6.50 in the next year. View Analyst Ratings for Celldex Therapeutics.

What are analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

  • 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
  • 2. Cowen and Company analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
  • 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Are investors shorting Celldex Therapeutics?

Celldex Therapeutics saw a decrease in short interest in the month of September. As of September 29th, there was short interest totalling 7,177,400 shares, a decrease of 42.3% from the September 15th total of 12,438,468 shares. Based on an average trading volume of 1,772,046 shares, the short-interest ratio is currently 4.1 days. Approximately 5.6% of the company's stock are short sold.

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

  • Larry Ellberger, Independent Chairman of the Board
  • Anthony S. Marucci, President, Chief Executive Officer, Director
  • Sam Martin, Chief Financial Officer, Senior Vice President
  • Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer
  • Thomas Andrew Davis M.D., Executive Vice President and Chief Medical Officer
  • Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Theresa M. LaVallee Ph.D., Senior Vice President - Regulatory and Precision Medicine
  • Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer`

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.96.


MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  485
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $6.50 (119.59% upside)
Consensus Price Target History for Celldex Therapeutics (NASDAQ:CLDX)
Price Target History for Celldex Therapeutics (NASDAQ:CLDX)
Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017Cantor FitzgeraldReiterated RatingBuy$9.00LowView Rating Details
8/9/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
6/29/2017AegisReiterated RatingBuyMediumView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
5/11/2017Jefferies Group LLCReiterated RatingHold$4.00 -> $3.50HighView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00N/AView Rating Details
3/7/2016Oppenheimer Holdings, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)
Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Earnings History by Quarter for Celldex Therapeutics (NASDAQ CLDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.27)N/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.23)$1.21 million$3.83 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.29)($0.28)$0.57 million$1.53 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.34)($0.30)$1.10 million$1.87 millionViewListenView Earnings Details
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)$1.02 million$1.03 millionViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$0.51 million$2.18 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/4/2014Q3($0.33)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.31)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.26)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
2017 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.30)($0.26)($0.28)
Q2 20173($0.27)($0.23)($0.26)
Q3 20173($0.28)($0.20)($0.24)
Q4 20173($0.29)($0.20)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celldex Therapeutics (NASDAQ:CLDX)
Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 56.69%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.00View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celldex Therapeutics (NASDAQ:CLDX)
Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
Source:
DateHeadline
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Short Interest Down 42.3% in September
www.americanbankingnews.com - October 13 at 1:32 AM
thestreet.com logoShort Interest Declines 42.3% For CLDX
www.thestreet.com - October 11 at 6:48 PM
americanbankingnews.com logoZacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - October 11 at 2:08 AM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 8 at 2:44 PM
fool.com logoWhat's Behind Celldex Therapeutics, Inc.'s 16% Rally in September? - Motley Fool
www.fool.com - October 6 at 5:29 PM
finance.yahoo.com logoWhat's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
finance.yahoo.com - October 6 at 5:29 PM
fool.com logoWhat's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
www.fool.com - October 6 at 4:45 PM
finance.yahoo.com logoCelldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs
finance.yahoo.com - October 3 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017
finance.yahoo.com - October 2 at 5:25 PM
finance.yahoo.com logoHow Does Investing In Celldex Therapeutics Inc (CLDX) Impact Your Portfolio?
finance.yahoo.com - October 2 at 5:25 PM
seekingalpha.com logoWhy Celldex Therapeutics Is A Buy (Part 2) - Seeking Alpha
seekingalpha.com - September 30 at 3:27 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates Buy Rating for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - September 27 at 6:10 PM
fool.com logoWhy Celldex Therapeutics, Inc. Jumped Higher Today
www.fool.com - September 25 at 4:29 PM
finance.yahoo.com logoCelldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 25, 2017
finance.yahoo.com - September 25 at 12:30 PM
americanbankingnews.com logoHead-To-Head Contrast: Celldex Therapeutics (CLDX) and The Competition
www.americanbankingnews.com - September 24 at 6:18 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Expected to Announce Quarterly Sales of $1.17 Million
www.americanbankingnews.com - September 24 at 3:44 AM
americanbankingnews.com logo Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - September 22 at 12:14 PM
finance.yahoo.com logoCelldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 9:59 AM
seekingalpha.com logoReasons Why Celldex Therapeutics Is A Buy (Part 1) - Seeking Alpha
seekingalpha.com - September 21 at 5:07 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 13 at 4:46 PM
globenewswire.com logoCelldex Announces Departure of Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - September 13 at 3:55 AM
streetinsider.com logoAfter-Hours Stock Movers 09/12: (SNAK) (JWN) (CNC) Higher; (AMRK) (TCMD) (CLDX) Lower (more...)
www.streetinsider.com - September 12 at 10:53 PM
finance.yahoo.com logoCelldex Announces Departure of Chief Medical Officer
finance.yahoo.com - September 12 at 5:53 PM
finance.yahoo.com logoETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 10:57 PM
finance.yahoo.com logoETFs with exposure to Celldex Therapeutics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:11 PM
finance.yahoo.com logoCelldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 29, 2017
finance.yahoo.com - August 29 at 5:40 PM
americanbankingnews.com logoCelldex Therapeutics (CLDX) versus OncoSec Medical (ONCS) Head-To-Head Review
www.americanbankingnews.com - August 29 at 4:10 AM
zacks.com logoCelldex Ends Phase II Enrollment for Breast Cancer Candidate
www.zacks.com - August 24 at 5:28 PM
finance.yahoo.com logoCelldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:28 PM
finance.yahoo.com logoCelldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
finance.yahoo.com - August 23 at 5:49 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 19 at 2:48 PM
americanbankingnews.com logo$1.17 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - August 18 at 11:32 AM
finance.yahoo.com logoCelldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : August 17, 2017
finance.yahoo.com - August 16 at 10:44 PM
americanbankingnews.com logo-$0.25 Earnings Per Share Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - August 16 at 9:42 AM
finance.yahoo.com logoCelldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 14, 2017
finance.yahoo.com - August 14 at 10:40 PM
americanbankingnews.com logoFY2017 EPS Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Reduced by Analyst
www.americanbankingnews.com - August 11 at 11:18 AM
finance.yahoo.com logoEdited Transcript of CLDX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:29 PM
americanbankingnews.com logoCelldex Therapeutics, Inc. (CLDX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - August 9 at 10:48 PM
seekingalpha.com logoCelldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 5:26 PM
nasdaq.com logoCelldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - August 9 at 5:26 PM
fool.com logoCelldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
www.fool.com - August 9 at 8:15 AM
rttnews.com logoEARNINGS SUMMARY: Details of Celldex Therapeutics Inc. Q2 Earnings Report
www.rttnews.com - August 8 at 10:03 PM
finance.yahoo.com logoCelldex reports 2Q loss
finance.yahoo.com - August 8 at 10:03 PM
globenewswire.com logoCelldex Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:00 PM
finance.yahoo.com logoCelldex Reports Second Quarter 2017 Results
finance.yahoo.com - August 8 at 5:00 PM
finance.yahoo.com logoCelldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 4, 2017
finance.yahoo.com - August 4 at 5:32 PM
americanbankingnews.com logoCritical Comparison: Celldex Therapeutics (NASDAQ:CLDX) and Compugen (CGEN)
www.americanbankingnews.com - August 3 at 8:40 AM
nasdaq.com logoWhat's in the Cards for Celldex (CLDX) this Earnings Season? - Nasdaq
www.nasdaq.com - August 2 at 6:00 PM
feeds.benzinga.com logoCelldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call
feeds.benzinga.com - August 2 at 12:38 PM
streetinsider.com logoUPDATE: HC Wainwright Assumes Celldex Therapeutics (CLDX) at Buy - StreetInsider.com
www.streetinsider.com - August 1 at 5:56 PM

Social

Chart

Celldex Therapeutics (CLDX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.